Ning‐Ping Zhang

1.1k total citations
28 papers, 768 citations indexed

About

Ning‐Ping Zhang is a scholar working on Epidemiology, Hepatology and Oncology. According to data from OpenAlex, Ning‐Ping Zhang has authored 28 papers receiving a total of 768 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Epidemiology, 10 papers in Hepatology and 9 papers in Oncology. Recurrent topics in Ning‐Ping Zhang's work include Liver Disease Diagnosis and Treatment (10 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Hepatitis B Virus Studies (5 papers). Ning‐Ping Zhang is often cited by papers focused on Liver Disease Diagnosis and Treatment (10 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Hepatitis B Virus Studies (5 papers). Ning‐Ping Zhang collaborates with scholars based in China, Canada and Netherlands. Ning‐Ping Zhang's co-authors include Harry L.A. Janssen, Bettina E. Hansen, Xizhong Shen, Jurriën G.P. Reijnders, Li Xie, Xuejing Liu, Jian Wu, Ling Dong, Jian Wu and Taotao Liu and has published in prestigious journals such as Gastroenterology, Hepatology and The FASEB Journal.

In The Last Decade

Ning‐Ping Zhang

26 papers receiving 761 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ning‐Ping Zhang China	13	495	337	215	104	87	28	768
Kunimaro Furuta Japan	17	405 0.8×	298 0.9×	293 1.4×	90 0.9×	55 0.6×	32	776
Kolade M. Agboola United States	9	516 1.0×	357 1.1×	340 1.6×	105 1.0×	78 0.9×	20	926
Zahra Ghiassi–Nejad United States	10	593 1.2×	373 1.1×	219 1.0×	79 0.8×	58 0.7×	22	905
Romain Désert United States	14	209 0.4×	168 0.5×	287 1.3×	82 0.8×	92 1.1×	28	694
Peri Kocabayoglu Germany	13	503 1.0×	448 1.3×	215 1.0×	121 1.2×	138 1.6×	20	985
Carolina Jiménez Calvente United States	4	410 0.8×	283 0.8×	406 1.9×	153 1.5×	22 0.3×	7	801
Tomoko Tadokoro Japan	20	286 0.6×	224 0.7×	400 1.9×	191 1.8×	129 1.5×	74	933
Hui‐Wei Chen United States	7	310 0.6×	337 1.0×	133 0.6×	181 1.7×	29 0.3×	12	636
Roman Liebe Germany	11	260 0.5×	192 0.6×	135 0.6×	37 0.4×	73 0.8×	36	468
Nobuko Serizawa Japan	7	205 0.4×	182 0.5×	145 0.7×	173 1.7×	61 0.7×	18	535

Countries citing papers authored by Ning‐Ping Zhang

Since Specialization

Citations

This map shows the geographic impact of Ning‐Ping Zhang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ning‐Ping Zhang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ning‐Ping Zhang more than expected).

Fields of papers citing papers by Ning‐Ping Zhang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ning‐Ping Zhang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ning‐Ping Zhang. The network helps show where Ning‐Ping Zhang may publish in the future.

Co-authorship network of co-authors of Ning‐Ping Zhang

This figure shows the co-authorship network connecting the top 25 collaborators of Ning‐Ping Zhang. A scholar is included among the top collaborators of Ning‐Ping Zhang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ning‐Ping Zhang. Ning‐Ping Zhang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wong, Susan, Yong‐Yu Yang, Hui Chen, et al.. (2025). New advances in novel pharmacotherapeutic candidates for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) between 2022 and 2024. Acta Pharmacologica Sinica. 46(5). 1145–1155. 1 indexed citations

Xie, Li, Hui Chen, Li Zhang, et al.. (2025). Suppressing MASH fibrotic progression by blocking succinate-GPR91 signaling in HSCs. Hepatology. 83(4). 888–906. 1 indexed citations

Wang, Yi, et al.. (2025). Development and validation of a machine learning-based clinical prediction model for monitoring liver injury in patients with pan-cancer receiving immunotherapy. International Journal of Medical Informatics. 203. 106036–106036. 1 indexed citations

Liu, Yi, Dan Zhao, Liwen Zhang, et al.. (2025). Functionalized Polymeric Microneedles for Transdermal Delivery of Ovalbumin Protein Antigen. Pharmaceutics. 17(6). 737–737. 2 indexed citations

Lv, Minzhi, et al.. (2024). Clinical characteristics and prognosis of liver injury induced by immune checkpoint inhibitors in patients with malignancies: A real‐world retrospective study. British Journal of Clinical Pharmacology. 90(11). 2870–2882. 4 indexed citations

Liu, Qing, Zhiguo Zou, Jinyi Lin, et al.. (2024). Tofacitinib for the treatment of immune-related adverse events in cancer immunotherapy: a multi-center observational study. Journal of Translational Medicine. 22(1). 803–803. 10 indexed citations

Liu, Hai‐Ning, Xiao‐Fan Wang, Ning‐Ping Zhang, et al.. (2023). Diagnostic and economic value of carcinoembryonic antigen, carbohydrate antigen 19-9, and carbohydrate antigen 72-4 in gastrointestinal cancers. World Journal of Gastroenterology. 29(4). 706–730. 9 indexed citations

Zhang, Guangcong, Ning‐Ping Zhang, Hai‐Ning Liu, et al.. (2022). microRNA-106b-5p Promotes Cell Growth and Sensitizes Chemosensitivity to Sorafenib by Targeting the BTG3/Bcl-xL/p27 Signaling Pathway in Hepatocellular Carcinoma. Journal of Oncology. 2022. 1–15. 9 indexed citations

Chen, Yanjie, Hao Wu, Ning‐Ping Zhang, et al.. (2022). IRF-2 inhibits cancer proliferation by promoting AMER-1 transcription in human gastric cancer. Journal of Translational Medicine. 20(1). 68–68. 7 indexed citations

10.

Yang, Yong‐Yu, Li Xie, Ning‐Ping Zhang, et al.. (2022). Updates on novel pharmacotherapeutics for the treatment of nonalcoholic steatohepatitis. Acta Pharmacologica Sinica. 43(5). 1180–1190. 36 indexed citations

11.

Sun, Jialei, Ning‐Ping Zhang, Guangcong Zhang, et al.. (2021). Tumor cell-imposed iron restriction drives immunosuppressive polarization of tumor-associated macrophages. Journal of Translational Medicine. 19(1). 347–347. 36 indexed citations

12.

Chen, Yanjie, Ling Dong, Taotao Liu, et al.. (2021). Interferon regulatory factor family influences tumor immunity and prognosis of patients with colorectal cancer. Journal of Translational Medicine. 19(1). 379–379. 22 indexed citations

13.

Dong, Pingping, Xiaoxiao Wang, Wenqing Tang, et al.. (2020). Dampened VEPH1 activates mTORC1 signaling by weakening the TSC1/TSC2 association in hepatocellular carcinoma. Journal of Hepatology. 73(6). 1446–1459. 30 indexed citations

14.

Sun, Dalong, Tiancheng Luo, Pingping Dong, et al.. (2020). CD86⁺/CD206⁺ tumor-associated macrophages predict prognosis of patients with intrahepatic cholangiocarcinoma. PeerJ. 8. e8458–e8458. 40 indexed citations

15.

Liu, Xuejing, Li Xie, Kuo Du, et al.. (2020). Succinate‐GPR‐91 receptor signalling is responsible for nonalcoholic steatohepatitis‐associated fibrosis: Effects of DHA supplementation. Liver International. 40(4). 830–843. 46 indexed citations

16.

Zhang, Ning‐Ping, Guangcong Zhang, Hai‐Ning Liu, et al.. (2020). microRNA-106b-5p Promotes Cell Growth and Sensitizes Chemosensitivity to Sorafenib by Targeting the BTG3/Bcl-xL/p27 Signaling Pathway in Hepatocellular Carcinoma. SSRN Electronic Journal. 2 indexed citations

17.

Weng, Shu‐Qiang, Harry L.A. Janssen, Ning‐Ping Zhang, et al.. (2019). CAPS1 Suppresses Tumorigenesis in Cholangiocarcinoma. Digestive Diseases and Sciences. 65(4). 1053–1063. 2 indexed citations

18.

Campenhout, Margo J. H. van, Willem Pieter Brouwer, Qing Xie, et al.. (2018). Long‐term follow‐up of patients treated with entecavir and peginterferon add‐on therapy for HBeAg‐positive chronic hepatitis B infection: ARES long‐term follow‐up. Journal of Viral Hepatitis. 26(1). 109–117. 14 indexed citations

19.

Zhang, Ning‐Ping, et al.. (2011). Frequency and clinical outcomes of flares related to nucleos(t)ide analogue therapy in patients with chronic hepatitis B. Journal of Viral Hepatitis. 18(7). e252–7. 14 indexed citations

20.

Reijnders, Jurriën G.P., et al.. (2010). Nucleos(t)ide Analogues Only Induce Temporary Hepatitis B e Antigen Seroconversion in Most Patients With Chronic Hepatitis B. Gastroenterology. 139(2). 491–498. 151 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact